Astera Labs CFO reports sell-to-cover sales and trust transfer on Form 4
Rhea-AI Filing Summary
Michael Truett Tate, Chief Financial Officer and Director of Astera Labs, Inc. (ALAB), reported routine insider transactions on Form 4. On 08/18/2025 he had automatic "sell-to-cover" sales of restricted stock units to satisfy tax withholding, selling 9,668 shares at a weighted-average price of $183.8343 and 9,193 shares at a weighted-average price of $183.1692. After those sales his direct beneficial ownership totals reported are 268,705 and 259,512 shares respectively. On 08/19/2025 he transferred 55,785 shares to the Tate 1997 Living Trust for no consideration and reported corresponding entries showing 203,727 shares held directly and 457,281 shares indirectly by the trust. The filing notes the transfers were non-discretionary sell-to-cover and the trustee disclaims beneficial ownership except for any pecuniary interest.
Positive
- Transparent disclosure of weighted-average sale prices and explicit explanation that sales were mandatory sell-to-cover for tax withholding.
- Timely compliance with Section 16 reporting via Form 4 and inclusion of ownership disclaimers regarding the trust.
- Detailed footnotes provide price ranges and offer to supply further breakdowns on request, aiding auditability.
Negative
- Reduction in direct holdings following sales and the transfer to the Tate Trust, which may reduce the reporting person’s direct share control.
- Limited context on whether the trust transfer affects voting power or future disposition, beyond a standard disclaimer.
Insights
TL;DR: Routine compliance filing showing automated tax-related sales and a non‑cash transfer to a family trust; no red flags disclosed.
The Form 4 documents standard post-vesting mechanics: mandated sell-to-cover transactions to satisfy tax withholding and a contemporaneous transfer of shares into a revocable living trust for estate or administrative purposes. Transactions are disclosed with weighted-average sale prices and an explicit disclaimer of beneficial ownership regarding the trust position. From a governance perspective the filing demonstrates timely disclosure and adherence to Section 16 reporting requirements.
TL;DR: Sales were automatic to cover tax obligations; transfer to a trust was a non‑cash estate planning move, not a market-timed disposition.
The sales are labeled as mandatory "sell-to-cover" tied to RSU settlement, with price ranges provided, which indicates these were liquidity actions for tax purposes rather than voluntary trading. The transfer of 55,785 shares to the Tate Trust for no consideration is consistent with estate planning or asset titling and is accompanied by a standard beneficial ownership disclaimer. There is sufficient granularity (prices ranges, counts) to reconcile the post-transaction holdings reported.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Gift | Common Stock | 55,785 | $0.00 | -- |
| Gift | Common Stock | 55,785 | $0.00 | -- |
| Sale | Common Stock | 9,668 | $183.8343 | $1.78M |
| Sale | Common Stock | 9,193 | $183.1692 | $1.68M |
Footnotes (1)
- Represents shares of the Issuer's Common Stock required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person. Such sales were automatic and mandated by an election of the Issuer made in advance of the vesting event to require the satisfaction of tax withholding obligations to be funded by a "sell to cover", and does not represent a discretionary trade by the Reporting Person. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $184.4400 to $183.4500, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $183.4400 to $182.8700, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. On August 19, 2025, the Reporting Person transferred 55,785 shares of Issuer Common Stock to Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust") for no consideration. These shares are owned directly by the Tate Trust, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
